CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-03-01 | Shih Alvin EVP of Research & Development | Sale | −8,750 | $14.35 | $126K | 175,834 |
| 2016-02-01 | VALEUR JENSEN MARGARET E General Counsel | Grant or award | +50,000 | 100,000 | ||
| 2016-01-27 | ASELAGE STEVE Chief Executive Officer | Gift | −3,000 | 305,756 | ||
| 2015-12-09 | Shih Alvin EVP of Research & Development | Sale | −8,750 | $20.83 | $182K | 184,584 |
| 2015-11-10 | ASELAGE STEVE Chief Executive Officer | Sale | −30,000 | $18.72 | $562K | 308,756 |
| 2015-11-09 | ASELAGE STEVE Chief Executive Officer | Sale | −30,000 | $18.77 | $563K | 338,756 |
| 2015-11-02 | VALEUR JENSEN MARGARET E General Counsel | Sale | −44,664 | $20.38 | $910K | 55,336 |
| 2015-11-02 | VALEUR JENSEN MARGARET E General Counsel | Sale | −5,336 | $21.12 | $113K | 50,000 |
| 2015-10-06 | Shih Alvin EVP of Research & Development | Sale | −4,798 | $19.58 | $94K | 197,286 |
| 2015-10-06 | Shih Alvin EVP of Research & Development | Sale | −2,823 | $20.45 | $58K | 194,463 |
| 2015-10-06 | Shih Alvin EVP of Research & Development | Sale | −1,129 | $21.61 | $24K | 193,334 |
| 2015-09-11 | ASELAGE STEVE Chief Executive Officer | Gift | −3,000 | 368,756 | ||
| 2015-07-01 | Clague Laura Chief Financial Officer | Grant or award · Employee stock option (right to buy) | +60,000 | 60,000 | ||
| 2015-07-01 | VALEUR JENSEN MARGARET E General Counsel | Grant or award · Employee stock option (right to buy) | +60,000 | 60,000 | ||
| 2015-07-01 | Shih Alvin EVP of Research & Development | Grant or award · Employee stock option (right to buy) | +60,000 | 60,000 | ||
| 2015-07-01 | ASELAGE STEVE Chief Executive Officer | Grant or award · Employee stock option (right to buy) | +150,000 | 150,000 | ||
| 2015-06-26 | Shih Alvin EVP of Research & Development | Sale | −27,916 | $32.70 | $913K | 202,084 |
| 2015-06-08 | LYONS GARY A Director | Grant or award | +2,000 | 22,000 | ||
| 2015-06-08 | LYONS GARY A Director | Grant or award · Employee Stock Option (Right to Buy) | +8,000 | 8,000 | ||
| 2015-06-08 | Golding Cornelius E Director | Grant or award | +2,000 | 27,000 |
Page 55 of 59 · 1,174 trades